A better acne treatment may be coming

Publication
Article
Contemporary PEDS JournalJune 2023
Volume 40
Issue 5

After 12 weeks of treatment, 55.8% of participants receiving IDP-126 experienced at least a 70% reduction from baseline in inflammatory and noninflammatory lesions

A better acne treatment may be coming | Image Credit: Contemporary Pediatrics®

A better acne treatment may be coming | Image Credit: Contemporary Pediatrics®

A fixed-dose, triple-combination formula being developed to treat acne is more effective against this teenage scourge than 3 traditional 2-component gels, according to a recent trial (NCT03170388).

The 394 pediatric participants with moderate to severe acne (mean age, 14.9 years) had a baseline evaluator’s global severity score of 3 (moderate). They were randomized to 12 weeks of once-daily treatment with one of 4 combination products, including the first fixed-dose, triple-combination product in development for acne treatment in patients 9 years or older: clindamycin phosphate, adapalene, and polymeric mesh gel (IDP-126). The other 3 products were dyad gels benzoyl peroxide (BPO)/adapalene; clindamycin phosphate/BPO; and clindamycin phosphate/adapalene. The 388 controls received vehicle gel, a dermatologic drug product that enhances delivery and efficacy of an active compound.

After 12 weeks of treatment, 55.8% of participants receiving IDP-126 experienced at least a 70% reduction from baseline in inflammatory and noninflammatory lesions. These reductions were significantly greater than those in patients treated with any of the dyad combinations (range, 30.8%-33.9%) or vehicle gel, whose reductions were less than two-thirds of those treated with IDP-126. Further, significant reductions in lesions were seen with IDP-126 as early as week 2 and persisted throughout the study.

In addition, compared with other treatment groups, participants who received IDP-126 experienced greater improvements in quality of life, as measured by the Acne-Specific Quality of Life Questionnaire, which covers 4 domains: self-perception, role-emotional, role-social, and acne symptoms. In the 1 exception, participants treated with clindamycin phosphate/adapalene experienced a greater improvement in the role-emotional domain than those in other treatment groups.

Teenage girl with acne | Image Credit: © New Africa - © New Africa - stock.adobe.com.

Teenage girl with acne | Image Credit: © New Africa - © New Africa - stock.adobe.com.

As to safety and tolerability, rates of treatment-emergent adverse events (TEAEs) were higher with IDP-126 than with the other treatments, although these were mostly mild or moderate in all groups, and no serious AEs were related to IDP-126. The most common TEAEs were application site pain and dryness. Only a few participants discontinued the trial because of a TEAE, with the highest rate in the BPO/adapalene group (4.8%).

THOUGHTS FROM DR FARBER:

We will see what happens with this. I do have 1 prediction: When the combination product is released (assuming it is available as a separate item), its cost will be much greater than the 3 components purchased individually.

Click here to read more from the June, 2023 issue of Contemporary Pediatrics®.

Reference:

Eichenfield LF, Stein Gold L, Kircik LH, et al. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: randomized phase 2 study. Pediatr Dermatol. Published online March 22, 2023. doi:10.1111/pde.15283 

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Russell Libby, MD, FAAP
Lawrence Eichenfield, MD
Wendy Ripple, MD
Wendy Ripple, MD
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
Related Content
© 2025 MJH Life Sciences

All rights reserved.